K-RAS GTPase- and B-RAF kinase-mediated T-cell tolerance defects in rheumatoid arthritis

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 25, 2012, Pages

  Singh, Karnail ^a   Deshpande, Pratima ^b   Li, Guangjin ^b   Yu, Mingcan ^b   Pryshchep, Sergey ^a   Cavanagh, Mary ^b   Weyand, Cornelia M ^b   Goronzy, Jörg J ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; RAS PROTEIN; T LYMPHOCYTE RECEPTOR;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CELL STIMULATION; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; MOLECULAR MECHANICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; T LYMPHOCYTE; WESTERN BLOTTING;

ARTHRITIS, RHEUMATOID; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENES, RAS; GTP PHOSPHOHYDROLASES; HUMANS; IMMUNE TOLERANCE; PROTO-ONCOGENE PROTEINS B-RAF; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES;

EID: 84862538572     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1117640109     Document Type: Article

References (53)

1. Goronzy JJ, Weyand CM (2005) Rheumatoid arthritis. Immunol Rev 204:55-73.
2. Fujii H, Shao L, Colmegna I, Goronzy JJ, Weyand CM (2009) Telomerase insufficiency in rheumatoid arthritis. Proc Natl Acad Sci USA 106:4360-4365.
3. Firestein GS (2003) Evolving concepts of rheumatoid arthritis. Nature 423:356-361.
4. Schellekens GA, de Jong BA, van den Hoogen FH, van de Putte LB, van Venrooij WJ (1998) Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 101:273-281.
5. Wegner N, et al. (2010) Autoimmunity to specific citrullinated proteins gives the first clues to the etiology of rheumatoid arthritis. Immunol Rev 233:34-54.
6. Goronzy JJ, Weyand CM (2009) Developments in the scientific understanding of rheumatoid arthritis. Arthritis Res Ther 11:249.
7. Kremer JM, et al. (2003) Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 349:1907-1915.
8. Weyand CM, Goronzy JJ (2006) T-cell-targeted therapies in rheumatoid arthritis. Nat Clin Pract Rheumatol 2:201-210.
9. Salomon B, Bluestone JA (2001) Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol 19:225-252.
10. Goronzy JJ, Weyand CM (2008) T-cell co-stimulatory pathways in autoimmunity. Arthritis Res Ther 10(suppl 1):S3.
11. Plenge RM, et al. (2005) Replication of putative candidate-gene associations with rheumatoid arthritis in >4,000 samples from North America and Sweden: Association of susceptibility with PTPN22, CTLA4, and PADI4. Am J Hum Genet 77:1044-1060.
12. Bottini N, Vang T, Cucca F, Mustelin T (2006) Role of PTPN22 in type 1 diabetes and other autoimmune diseases. Semin Immunol 18:207-213.
13. Zhang J, et al. (2011) The autoimmune disease-associated PTPN22 variant promotes calpain-mediated Lyp/Pep degradation associated with lymphocyte and dendritic cell hyperresponsiveness. Nat Genet 43:902-907.
14. Cope AP (2004) Altered signalling thresholds in T lymphocytes cause autoimmune arthritis. Arthritis Res Ther 6:112-116.
15. Weyand CM, Fulbright JW, Goronzy JJ (2003) Immunosenescence, autoimmunity, and rheumatoid arthritis. Exp Gerontol 38:833-841.
16. Singh K, et al. (2009) ERK-dependent T cell receptor threshold calibration in rheumatoid arthritis. J Immunol 183:8258-8267.
17. Jeffrey KL, Camps M, Rommel C, Mackay CR (2007) Targeting dual-specificity phosphatases: Manipulating MAP kinase signalling and immune responses. Nat Rev Drug Discov 6:391-403.
18. Bryl E, et al. (2005) Modulation of CD28 expression with anti-tumor necrosis factor alpha therapy in rheumatoid arthritis. Arthritis Rheum 52:2996-3003.
19. Cope AP, et al. (1997) Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling. J Exp Med 185:1573-1584.
20. O'Shea CC, Crompton T, Rosewell IR, Hayday AC, Owen MJ (1996) Raf regulates positive selection. Eur J Immunol 26:2350-2355.
21. Feinerman O, Veiga J, Dorfman JR, Germain RN, Altan-Bonnet G (2008) Variability and robustness in T cell activation from regulated heterogeneity in protein levels. Science 321:1081-1084.
22. Fischer A, et al. (2009) Regulation of RAF activity by 14-3-3 proteins: RAF kinases associate functionally with both homo- and heterodimeric forms of 14-3-3 proteins. J Biol Chem 284:3183-3194.
23. Yeung K, et al. (1999) Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP. Nature 401:173-177.
24. Trakul N, Menard RE, Schade GR, Qian Z, Rosner MR (2005) Raf kinase inhibitory protein regulates Raf-1 but not B-Raf kinase activation. J Biol Chem 280:24931-24940.
25. Hill JA, et al. (2003) Cutting edge: The conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLADRB1* 0401 MHC class II molecule. J Immunol 171:538-541.
26. Stefanová I, et al. (2003) TCR ligand discrimination is enforced by competing ERK positive and SHP-1 negative feedback pathways. Nat Immunol 4:248-254.
27. Altan-Bonnet G, Germain RN (2005) Modeling T cell antigen discrimination based on feedback control of digital ERK responses. PLoS Biol 3:e356.
28. Dillon TJ, et al. (2003) Ectopic B-Raf expression enhances extracellular signal-regulated kinase (ERK) signaling in T cells and prevents antigen-presenting cell-induced anergy. J Biol Chem 278:35940-35949.
29. Minato N, Kometani K, Hattori M (2007) Regulation of immune responses and hematopoiesis by the Rap1 signal. Adv Immunol 93:229-264.
30. Oliveira JB, et al. (2007)NRASmutation causes a human autoimmune lymphoproliferative syndrome. Proc Natl Acad Sci USA 104:8953-8958.
31. Cope AP (2008) T cells in rheumatoid arthritis. Arthritis Res Ther 10(suppl 1):S1.
32. Shao L, et al. (2009) Deficiency of the DNA repair enzyme ATM in rheumatoid arthritis. J Exp Med 206:1435-1449.
33. Koetz K, et al. (2000) T cell homeostasis in patients with rheumatoid arthritis. Proc Natl Acad Sci USA 97:9203-9208.
34. Wagner UG, Koetz K, Weyand CM, Goronzy JJ (1998) Perturbation of the T cell repertoire in rheumatoid arthritis. Proc Natl Acad Sci USA 95:14447-14452.
35. Ponchel F, et al. (2002) Dysregulated lymphocyte proliferation and differentiation in patients with rheumatoid arthritis. Blood 100:4550-4556.
36. Burgoyne CH, et al. (2008) Abnormal T cell differentiation persists in patients with rheumatoid arthritis in clinical remission and predicts relapse. Ann Rheum Dis 67:750-757.
37. Zikherman J, Weiss A (2009) Antigen receptor signaling in the rheumatic diseases. Arthritis Res Ther 11:202.
38. Thomas R, Turner M, Cope AP (2008) High avidity autoreactive T cells with a low signalling capacity through the T-cell receptor: Central to rheumatoid arthritis pathogenesis? Arthritis Res Ther 10:210.
39. Zouali M, Sarmay G (2004) B lymphocyte signaling pathways in systemic autoimmunity: Implications for pathogenesis and treatment. Arthritis Rheum 50:2730-2741.
40. O'Keefe TL, Williams GT, Batista FD, Neuberger MS (1999) Deficiency in CD22, a B cell-specific inhibitory receptor, is sufficient to predispose to development of high affinity autoantibodies. J Exp Med 189:1307-1313.
41. Fukuyama H, Nimmerjahn F, Ravetch JV (2005) The inhibitory Fcgamma receptor modulates autoimmunity by limiting the accumulation of immunoglobulin G+ anti-DNA plasma cells. Nat Immunol 6:99-106.
42. Zikherman J, et al. (2009) PTPN22 deficiency cooperates with the CD45 E613R allele to break tolerance on a non-autoimmune background. J Immunol 182:4093-4106.
43. Crispín JC, Kyttaris VC, Juang YT, Tsokos GC (2008) How signaling and gene transcription aberrations dictate the systemic lupus erythematosus T cell phenotype. Trends Immunol 29:110-115.
44. Loeser S, Penninger JM (2007) Regulation of peripheral T cell tolerance by the E3 ubiquitin ligase Cbl-b. Semin Immunol 19:206-214.
45. Sakaguchi S, et al. (2006) Spontaneous development of autoimmune arthritis due to genetic anomaly of T cell signal transduction: Part 1. Semin Immunol 18:199-206.
46. Sommers CL, et al. (2002) A LAT mutation that inhibits T cell development yet induces lymphoproliferation. Science 296:2040-2043.
47. Aguado E, et al. (2002) Induction of T helper type 2 immunity by a point mutation in the LAT adaptor. Science 296:2036-2040.
48. Li QJ, et al. (2007) miR-181a is an intrinsic modulator of T cell sensitivity and selection. Cell 129:147-161.
49. Hickman SP, Yang J, Thomas RM, Wells AD, Turka LA (2006) Defective activation of protein kinase C and Ras-ERK pathways limits IL-2 production and proliferation by CD4+CD25+ regulatory T cells. J Immunol 177:2186-2194.
50. Boussiotis VA, Freeman GJ, Berezovskaya A, Barber DL, Nadler LM (1997) Maintenance of human T cell anergy: blocking of IL-2 gene transcription by activated Rap1. Science 278:124-128.
51. Gollob JA, Wilhelm S, Carter C, Kelley SL (2006) Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin Oncol 33:392-406.
52. Mason CS, et al. (1999) Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation. EMBO J 18:2137-2148.
53. Chakraborty AK, et al. (2009) Molecular origin and functional consequences of digital signaling and hysteresis during Ras activation in lymphocytes. Sci Signal 2:pt2.